Skip to main content

3 Result(s)

within M Ychou Remove this filter Medicine & Public Health Remove this filter Cancer Research Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

    Abstract

    M. Ychou, J. Raoul, F. Desseigne, C. Borel… in Cancer Chemotherapy and Pharmacology (2002)

  2. No Access

    Article

    Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases

    To assess the rate of R0 resection of liver metastases achieved after chemotherapy with FOLFIRINOX.

    M. Ychou, F. Viret, A. Kramar, F. Desseigne… in Cancer Chemotherapy and Pharmacology (2008)

  3. No Access

    Article

    Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX

    Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.

    T. Mazard, M. Ychou, S. Thezenas, S. Poujol… in Cancer Chemotherapy and Pharmacology (2012)